![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NPS ANNOUNCES RESULTS OF TEDUGLUTIDE TRIAL
NPS ANNOUNCES RESULTS OF TEDUGLUTIDE TRIAL
August 19, 2005
NPS Pharmaceuticals announced that results from a Phase II clinical trial with
the investigational drug teduglutide in subjects with short bowel syndrome (SBS),
published in the September issue of the gastroenterology journal Gut, showed
that daily subcutaneous injections of teduglutide achieved significant growth
of the intestinal lining and improved dietary absorption of nutrients and fluids.
Teduglutide is a proprietary analog of the naturally occurring hormone glucagon-like
peptide-2. In the study, teduglutide was given by subcutaneous injection for
21 days to 16 patients with SBS. Nutrient balance studies and intestinal mucosa
biopsies were done for all patients at the beginning of the study to establish
baseline measurements of intestinal function, then during the last three days
of treatment and again after three weeks of no treatment at a follow-up exam.
Results of the study showed that teduglutide significantly increased absolute
and relative wet weight absorption, urine weight and urine sodium excretion
all of which are important measurements of the drug's potential to lower SBS
patient's intravenous fluid requirements.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct